New vaccine aims to block HPV cancers missed by current shots
NCT ID NCT05985681
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new vaccine called RG1-VLP in 18 healthy women aged 18-60. The vaccine targets HPV types not covered by existing vaccines like Gardasil 9. Researchers will check if it is safe and triggers a strong immune response. If it works, it could help prevent more HPV-related cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RG1-VLP vaccine (HPV16 virus-like particle vaccine)
- What this could lead to
- If successful, this could lead to a vaccine that protects against HPV types not covered by current vaccines, potentially preventing more HPV-related cancers.
- What could go wrong
- This is a very early Phase 1 trial with only 18 participants, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS-RELATED CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
WITHDRAWNBaltimore, Maryland, 21287, United States
-
Medical University Vienna
NOT_YET_RECRUITINGVienna, A-1090, Austria
-
Staten Island University Hospital
WITHDRAWNStaten Island, New York, 10305, United States
-
University of Alabama at Birmingham Cancer Center
WITHDRAWNBirmingham, Alabama, 35233, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
RECRUITINGMadison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- At-Home cervical cancer screening could save lives in rural uganda
- Could a delayed booster still protect against HPV?
- Free HPV shots help prevent cancer in Low-Income adults
- Engineered immune cells take on HPV cancers in early trial
- Can a Pre-Transplant HPV shot shield patients from cancer?
- Could a 3-Week radiation blast tame HPV throat cancer?